End-of-day quote
Taiwan S.E.
03:30:00 10/05/2024 am IST
|
5-day change
|
1st Jan Change
|
713
TWD
|
-0.28%
|
|
-4.42%
|
+11.58%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
5,609
|
10,634
|
12,446
|
31,121
|
64,612
|
71,864
|
-
|
Enterprise Value (EV)
1 |
6,574
|
12,501
|
13,431
|
31,121
|
64,612
|
77,743
|
73,068
|
P/E ratio
|
18
x
|
18.4
x
|
16.7
x
|
22.7
x
|
21.2
x
|
22.5
x
|
15.3
x
|
Yield
|
1.4%
|
1.02%
|
1.9%
|
-
|
-
|
1.89%
|
1.81%
|
Capitalization / Revenue
|
3.67
x
|
5.91
x
|
2.54
x
|
2.97
x
|
4.55
x
|
3.9
x
|
3.35
x
|
EV / Revenue
|
4.3
x
|
6.95
x
|
2.74
x
|
2.97
x
|
4.55
x
|
4.22
x
|
3.41
x
|
EV / EBITDA
|
14.2
x
|
34.1
x
|
10.7
x
|
13.8
x
|
11
x
|
12.9
x
|
10.4
x
|
EV / FCF
|
-14.1
x
|
438
x
|
12.5
x
|
17.1
x
|
-
|
33.3
x
|
15.9
x
|
FCF Yield
|
-7.08%
|
0.23%
|
7.99%
|
5.86%
|
-
|
3.01%
|
6.29%
|
Price to Book
|
3.33
x
|
4.29
x
|
3.99
x
|
6.87
x
|
-
|
6.55
x
|
4.82
x
|
Nbr of stocks (in thousands)
|
91,161
|
96,417
|
96,687
|
97,524
|
1,01,115
|
1,00,791
|
-
|
Reference price
2 |
61.52
|
110.3
|
128.7
|
319.1
|
639.0
|
713.0
|
713.0
|
Announcement Date
|
16/03/20
|
29/03/21
|
09/03/22
|
20/03/23
|
07/03/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
1,529
|
1,800
|
4,900
|
10,494
|
14,200
|
18,426
|
21,456
|
EBITDA
1 |
464.5
|
367.1
|
1,256
|
2,263
|
5,855
|
6,007
|
6,993
|
EBIT
1 |
344.8
|
226.1
|
1,046
|
1,922
|
5,249
|
5,536
|
6,847
|
Operating Margin
|
22.55%
|
12.56%
|
21.35%
|
18.32%
|
36.97%
|
30.04%
|
31.91%
|
Earnings before Tax (EBT)
1 |
325.4
|
595.4
|
1,024
|
1,840
|
4,064
|
4,346
|
6,184
|
Net income
1 |
305
|
578.4
|
749.7
|
1,392
|
3,030
|
3,215
|
4,706
|
Net margin
|
19.95%
|
32.14%
|
15.3%
|
13.26%
|
21.34%
|
17.45%
|
21.93%
|
EPS
2 |
3.411
|
5.989
|
7.703
|
14.09
|
30.20
|
31.71
|
46.52
|
Free Cash Flow
1 |
-465.6
|
28.56
|
1,073
|
1,822
|
-
|
2,337
|
4,597
|
FCF margin
|
-30.44%
|
1.59%
|
21.9%
|
17.36%
|
-
|
12.68%
|
21.43%
|
FCF Conversion (EBITDA)
|
-
|
7.78%
|
85.43%
|
80.54%
|
-
|
38.9%
|
65.73%
|
FCF Conversion (Net income)
|
-
|
4.94%
|
143.14%
|
130.92%
|
-
|
72.68%
|
97.69%
|
Dividend per Share
2 |
0.8635
|
1.123
|
2.449
|
-
|
-
|
13.50
|
12.88
|
Announcement Date
|
16/03/20
|
29/03/21
|
09/03/22
|
20/03/23
|
07/03/24
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
1,189
|
1,150
|
1,117
|
1,355
|
2,724
|
5,298
|
4,781
|
3,139
|
3,075
|
3,206
|
2,857
|
5,062
|
5,202
|
5,436
|
5,225
|
EBITDA
1 |
272.4
|
237.7
|
305
|
421.5
|
-
|
-
|
1,681
|
1,485
|
1,370
|
1,320
|
1,293
|
1,609
|
1,788
|
2,037
|
-
|
EBIT
1 |
216.8
|
186.3
|
251.6
|
369.4
|
643.3
|
657.8
|
1,547
|
1,347
|
1,219
|
1,320
|
1,004
|
1,411
|
1,548
|
1,588
|
1,526
|
Operating Margin
|
18.24%
|
16.2%
|
22.52%
|
27.27%
|
23.62%
|
12.42%
|
32.37%
|
42.91%
|
39.64%
|
41.18%
|
35.12%
|
27.87%
|
29.75%
|
29.2%
|
29.21%
|
Earnings before Tax (EBT)
1 |
205.9
|
182.3
|
253
|
369.1
|
782
|
435.9
|
1,442
|
1,019
|
923
|
679.7
|
699
|
1,096
|
1,233
|
1,274
|
1,276
|
Net income
1 |
137.7
|
140.1
|
179.2
|
240
|
568.9
|
403.9
|
1,039
|
692
|
733.2
|
565.6
|
510.5
|
808
|
911.5
|
942
|
933
|
Net margin
|
11.58%
|
12.18%
|
16.04%
|
17.72%
|
20.88%
|
7.62%
|
21.74%
|
22.05%
|
23.84%
|
17.64%
|
17.87%
|
15.96%
|
17.52%
|
17.33%
|
17.86%
|
EPS
2 |
1.413
|
1.420
|
1.826
|
2.463
|
5.813
|
4.003
|
10.49
|
8.810
|
7.280
|
6.090
|
5.030
|
7.960
|
8.975
|
9.280
|
9.220
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/11/21
|
09/03/22
|
10/05/22
|
12/08/22
|
14/11/22
|
20/03/23
|
12/05/23
|
14/08/23
|
09/11/23
|
07/03/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
1 |
965
|
1,867
|
985
|
-
|
-
|
5,879
|
1,204
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
2.078
x
|
5.087
x
|
0.7841
x
|
-
|
-
|
0.9787
x
|
0.1721
x
|
Free Cash Flow
1 |
-466
|
28.6
|
1,073
|
1,822
|
-
|
2,337
|
4,597
|
ROE (net income / shareholders' equity)
|
20.5%
|
28.1%
|
26.7%
|
36.2%
|
-
|
27.4%
|
40.6%
|
ROA (Net income/ Total Assets)
|
10.9%
|
11.1%
|
10.4%
|
9.24%
|
-
|
11.1%
|
12.9%
|
Assets
1 |
2,807
|
5,192
|
7,188
|
15,067
|
-
|
28,895
|
36,526
|
Book Value Per Share
2 |
18.50
|
25.70
|
32.20
|
46.40
|
-
|
109.0
|
148.0
|
Cash Flow per Share
2 |
2.580
|
1.840
|
12.70
|
-
|
-
|
35.30
|
33.80
|
Capex
1 |
697
|
149
|
163
|
188
|
-
|
280
|
233
|
Capex / Sales
|
45.6%
|
8.29%
|
3.34%
|
1.79%
|
-
|
1.52%
|
1.08%
|
Announcement Date
|
16/03/20
|
29/03/21
|
09/03/22
|
20/03/23
|
07/03/24
|
-
|
-
|
Average target price
865
TWD Spread / Average Target +21.32% Consensus |
1st Jan change
|
Capi.
|
---|
| +11.58% | 221.37Cr | | +30.38% | 68TCr | | +29.32% | 57TCr | | -4.36% | 36TCr | | +19.30% | 33TCr | | +3.73% | 28TCr | | +16.35% | 24TCr | | +8.74% | 21TCr | | -7.81% | 20TCr | | +7.68% | 17TCr |
Other Pharmaceuticals
|